Hinterberger W, Gadner H, Höcker P, Hajek-Rosenmayr A, Graninger W, Grabner G, Volc-Platzer B, Hawliczek R, Kärcher K H, Kallinger W
Blut. 1987 Mar;54(3):137-46. doi: 10.1007/BF00320367.
Survival and quality of life are reported in 23 pretransfused patients with severe aplastic anemia (SAA) who underwent bone marrow transplantation (BMT). The projected survival is 76% with 18 of 23 patients being alive 332 to 1677 days post graft (median: 842). 5 patients died between day 4 and 416. 12 of 17 patients at risk developed chronic graft versus host disease (GVH-D). 4 of these patients have a diminished quality of life due GVH-D related disabling manifestations. Autologous haemopoietic recovery was excluded in all patients by the demonstration of haemopoietic chimerism. We recommand age-adapted rejection prophylaxis; such strategy may help to diminish disabling graft versus host disease in otherwise haematologically reconstituted survivors.
报告了23例接受骨髓移植（BMT）的输血前严重再生障碍性贫血（SAA）患者的生存情况和生活质量。预计生存率为76%，23例患者中有18例在移植后332至1677天存活（中位数：842天）。5例患者在第4天至416天之间死亡。17例有风险的患者中有12例发生了慢性移植物抗宿主病（GVH-D）。其中4例患者因GVH-D相关的致残表现而生活质量下降。通过造血嵌合体的证明排除了所有患者的自体造血恢复情况。我们建议采用适合年龄的排斥预防措施；这种策略可能有助于减少血液学重建幸存者中致残性移植物抗宿主病的发生。
